Nexus Energy Services Inc (IBGR)

[TheFinalCD]

Howard Phykitt commented:

"The first phase of money has been raised, enabling us to produce the product, but only in the area of a few million dollars a year in sales...

I've got this product perfected now. It is fully developed... There is no potassium-based aspirin in the world. There are sodium-based ones and calcium-based ones in Europe, which are very successful products."

An earlier version of Aquaprin (protected with three patents) was not a success after being marketed through a national broker network in the US. The new version, perfected in late 2007, will be sold in small foil packets containing a single granular dose for mixing with water. The facility will employ 25 personnel in the first year of production and will then expand into a new 100,000ft² plant on the same site in phase two when there will be an additional 150 personnel employed. Personnel are being trained at Nash Community College and production personnel are expected to be hired within 12 months.

The Aquaprin product will be in stores for sale in around 15 months (by November 2009). Aquaprin will be manufactured in accordance with the current FDA Analgesics Monograph in the 'permitted combinations' section of the Federal Register and in the USP under the 'Effervescent Aspirin' monograph.